A Nitroreductase-Activatable Lapachol Against Bacillus subtilis Unveils Antimicrobial Specificity.

Area of Science:

• Natural Product Chemistry
• Antimicrobial Resistance
• Drug Development

Background:

• Lapachol exhibits antimicrobial properties but possesses toxicity to mammalian cells, limiting its therapeutic application.
• Antimicrobial resistance necessitates the development of novel therapeutic strategies and drug delivery systems.

Purpose of the Study:

• To design and synthesize a lapachol prodrug that leverages bacterial nitroreductase for targeted drug release.
• To evaluate the efficacy and selectivity of the lapachol prodrug against bacterial infections while minimizing mammalian cell toxicity.

Main Methods:

• Synthesis of a lapachol prodrug designed for nitroreductase-mediated activation.
• In vitro studies using purified nitroreductase and bacterial cultures (Bacillus subtilis) to confirm lapachol release.
• Colony formation assays to assess bacterial toxicity and mammalian cell culture to evaluate cytotoxicity.

Main Results:

• Successful synthesis and characterization of the lapachol prodrug.
• Demonstrated release of active lapachol from the prodrug by bacterial nitroreductase in vitro and in Bacillus subtilis.
• Achieved comparable antibacterial efficacy to free lapachol with significantly reduced toxicity to mammalian cells (>10-fold selectivity).

Conclusions:

• The developed lapachol prodrug offers a promising strategy for targeted antimicrobial therapy.
• This approach effectively overcomes the toxicity limitations of free lapachol, enhancing its potential for treating bacterial infections.
• The prodrug exhibits significant selectivity, targeting bacteria while sparing healthy mammalian cells.